Gsk
May 16, 2012 at 14:42 | Source: Moneycontrol.com
May 14, 2012 at 09:49 | Source: CNBC-TV18
May 07, 2012 at 18:00 | Source: Moneycontrol.com
May 07, 2012 at 15:19 | Source: Moneycontrol.com
May 07, 2012 at 08:05 | Source: CNBC-TV18
Apr 26, 2012 at 15:26 | Source: CNBC-TV18
News across the web »
May 25, 2012 at 16:22 | Source: Market Watch
May 24, 2012 at 06:00 | Source: Business Week
May 23, 2012 at 01:36 | Source: Business Standard
May 22, 2012 at 22:11 | Source: The Hindu BusinessLine
May 22, 2012 at 11:06 | Source: Economic Times
Interact & exchange stock tips & market info »
Related News »
GlaxoSmithKline ($GSK) has shown in a series of M&A and investment moves that the London-based drug giant prefers to bet on known commodities--existing biotech partners. Bloomberg analyzed GSK's strategy and speculates that the company could ...
May 25, 2012 at 14:52 | Source: FierceBiotech
GlaxoSmithKline PLC (GSK) - GSK amends HGS tender offer conditions RNS Number : 9539D GlaxoSmithKline PLC 23 May 2012 Issued: Wednesday 23 May 2012, London UK GSK amends tender offer conditions to address Human Genome Sciences ...
May 23, 2012 at 12:31 | Source: Bloomberg
(RTTNews) - GlaxoSmithKline plc (GSK: News ,GSK.L: News ) said it has amended the conditions of its tender offer to buy all of the outstanding shares of Human Genome Sciences (HGSI: News ) for $13.00 per share in cash to address the HGS Board of Directors ...
May 23, 2012 at 12:38 | Source: RTT News
(RTTNews) - GlaxoSmithKline plc (GSK: News ,GSK.L: News ) Wednesday amended the conditions of its unsolicited tender offer to acquire Human Genome Sciences (HGSI: News ) for $13.00 per share. The move, the British drug maker said, is in response to a ...
May 23, 2012 at 17:25 | Source: RTT News
GlaxoSmithKline said it amended the conditions of its tender offer to acquire U.S. biotechnology company Human Genome Sciences in an attempt to address the target company's rights plan, which GSK called a "poison pill". Human Genome adopted a ...
May 23, 2012 at 12:53 | Source: International Business Times
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that’s part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI) (HGSI), its partner on the drug.
May 24, 2012 at 21:20 | Source: Businessweek
GSK receives positive opinion from European CHMP for pazopanib in the treatment of patients with cer
For the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only ...
May 27, 2012 at 06:00 | Source: PR-USA.net
GlaxoSmithKline plc (LSE: GSK) today commented on Human Genome Sciences (NASDAQ: HGSI) Board of Directors' decision to recommend against GSK's tender offer to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
May 17, 2012 at 17:32 | Source: FOXBusiness
Human Genome Sciences (HGSI) is doing whatever it can to avoid a hostile takeover by GlaxoSmithKline (GSK). The company says it's talking to what it calls "major" pharmaceutical and biotechnology companies to keep GlaxoSmithKline away.
May 18, 2012 at 13:34 | Source: MSN Money
GlaxoSmithKline plc (NYSE: GSK) commented on Human Genome Sciences (Nasdaq: HGSI) Board of Directors' decision to recommend against GSK’s tender offer to acquire all of the outstanding shares of HGS for $13.00 per share in cash. The offer represents a ...
May 17, 2012 at 17:10 | Source: StreetInsider.com